South Africa Orders Urgent Recall of Compounded Weight-Loss Drugs
Africa Africa Markets & Investment South Africa Orders Urgent Recall of Compounded Weight-Loss Drugs By Amina Diarra · July 25, 2026 · 6 min read Africa Intelligence A daily Africa read from a Latin American newsroom. SAHPRA ordered a Class I, Type A recall of compounded semaglutide and tirzepatide products made by iDexis/Sentra Pharmacy. —The warning. Prescribers and pharmacists face fines from R25,000 to R75,000 (about US$1,500–US$4,600) and potential loss of licence. —The court case.
- ▪Africa Africa Markets & Investment South Africa Orders Urgent Recall of Compounded Weight-Loss Drugs By Amina Diarra · July 25, 2026 · 6 min read Africa Intelligence A daily Africa read from a Latin American newsroom.
- ▪SAHPRA ordered a Class I, Type A recall of compounded semaglutide and tirzepatide products made by iDexis/Sentra Pharmacy. —The warning.
- ▪Prescribers and pharmacists face fines from R25,000 to R75,000 (about US$1,500–US$4,600) and potential loss of licence. —The court case.
The Rio Times publishes from Brazil and files mainly under world. We currently carry 349 of its stories.
Opening excerpt (first ~120 words) tap to expand
Africa Africa Markets & Investment South Africa Orders Urgent Recall of Compounded Weight-Loss Drugs By Amina Diarra · July 25, 2026 · 6 min read Africa Intelligence A daily Africa read from a Latin American newsroom. Free. Subscribe By subscribing you agree to our privacy policy. We never share your email. Africa · Southern Key Facts —The recall. SAHPRA ordered a Class I, Type A recall of compounded semaglutide and tirzepatide products made by iDexis/Sentra Pharmacy. —The warning. Prescribers and pharmacists face fines from R25,000 to R75,000 (about US$1,500–US$4,600) and potential loss of licence. —The court case. Novo Nordisk won an interim High Court order barring iDexis from manufacturing or selling semaglutide-based medicines. —The scale.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Rio Times.
Discussion
0 commentsMore from The Rio Times
